Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China · Delayed Price · Currency is CNY

24.06

-1.54 (-6.02%)

Sep 11, 2026, 3:00 PM CST

Market Cap	10.40B -48.2%
Revenue (ttm)	873.99M +371.4%
Net Income	-939.72M
EPS	-2.31
Shares Out	445.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,590,028
Open	25.83
Previous Close	25.60
Day's Range	23.92 - 25.99
52-Week Range	23.92 - 58.03
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 30, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 1,325

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688062

Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial Statements